FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington,	D.C.	20549
-------------	------	-------

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Levy Elliott M.				2. Issuer Name and Ticker or Trading Symbol Omega Therapeutics, Inc. [OMGA]					(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/07/2023							(give title	Other (s below)	·	
C/O OM	EGA THE	RAPEUTICS, IN	IC.		4. If <i>i</i>	Amer	ndment, I	Date	of Original Fil	ed (Month/D	Day/Year)	6. 1	ndividual or	Joint/Group Fil	ing (Check Ap	plicable
140 FIRST STREET, SUITE 501										- 1	Line) X Form filed by One Reporting Person					
(Street)	IDGE M	Δ	02141		,									iled by More th		
CAMBRIDGE WA 02141			Ru	Rule 10b5-1(c) Transaction Indication												
(City)	(S	tate)	(Zip)		$ _{\Box}$	Checl	k this box	to ind	•	nsaction was	made pursua	ant to a con	tract, instructi on 10.	on or written pla	n that is intende	ed to
		Tab	le I - Non-	Deriv	ative	Sec	urities	Ac	quired, Di	sposed	of, or Be	neficial	ly Owne	t		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,		r) Code (Inst	Transaction Code (Instr. 3 5) 5) (A) or		str. 3, 4 an	Benefici	es Forn ally (D) o following (I) (II	rm: Direct () or Indirect ((Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code V Amount (A) 01 (D)				Price	(Instr. 3						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date (Month/Day/Year) if any		ate,	4. Transaction of Code (Instr. 8) Securiti Acquire (A) or Dispose of (D) (Instr. 3 and 5)		ive ies ed	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$8.39	06/07/2023			A		18,118		(1)	06/06/2033	Common Stock	18,118	\$0.00	18,118	D	

Explanation of Responses:

1. The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Remarks:

/s/ Barbara Chan as Attorney-

in-Fact for Elliott M. Levy,

M.D.

** Signature of Reporting Person

06/09/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.